Name That Brand: April 2012

Share this article:

Can you name the brand? Each month we print part of a popular pharmaceutical product or advertisement, along with clues to its identity. Readers are invited to name the brand for a chance to win a copy of Medicine Ave 2: The Story of Medical Advertising in America 1990-2008. E-mail your answer to NameThatBrand@haymarketmedia.com or fax 646-638-6150. The deadline is April 30, 2012. The winner will be picked randomly from the correct entries.

Brand X puts its best feet forward
This first-to-market drug earned its manufacturer roughly $2 billion in revenues last year. Initially approved in 2003 to treat a befuddling, nebulous condition, it has expanded to include at least four others. While the conditions the drug treats have names and treatment plans, just how it quiets the symptoms is a mystery. This spot is just one take on evoking a patient's frame of mind; the brand has also used of portraits and lifestyle shots that highlight the mental and physical toll of this painful condition.

FEBRUARY'S WINNER...
Congratulations to Carly Kuper, VP, Strategic Marketing & Corporate Communications at CMI Communications Media Inc., who correctly guessed Nicorette, Glaxo­SmithKline's product to help cigarette smokers quit.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?